awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34742904-D0E4D52D-7C24-4660-B8AF-EBF30C06F17D
Q34742904-D0E4D52D-7C24-4660-B8AF-EBF30C06F17D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34742904-D0E4D52D-7C24-4660-B8AF-EBF30C06F17D
Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway.
P2860
Q34742904-D0E4D52D-7C24-4660-B8AF-EBF30C06F17D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34742904-D0E4D52D-7C24-4660-B8AF-EBF30C06F17D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3b4ec619627315b152c8abb5cf07f38589a7bb6c
P2860
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.